Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery
- PMID: 29438688
- DOI: 10.1016/j.ccell.2018.01.014
Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery
Abstract
In this issue of Cancer Cell, Jeselsohn et al. dissect the function of several of the most clinically important estrogen receptor alpha mutants associated with endocrine therapy resistance in breast cancer and demonstrate that they manifest disease-relevant neomorphic activities that likely contribute to tumor pathogenesis.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.Cancer Cell. 2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004. Cancer Cell. 2018. PMID: 29438694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources